Drug Profile
Oxytocin intranasal - OptiNose
Alternative Names: OPN-300; OptiNose oxytocinLatest Information Update: 07 Dec 2022
Price :
$50
*
At a glance
- Originator OptiNose
- Class Amides; Amines; Analgesics; Antihaemorrhagics; Antihyperglycaemics; Antimigraines; Behavioural disorder therapies; Hormones; Macrocyclic lactams; Obesity therapies; Oxytocics; Peptides; Pyrrolidines; Small molecules
- Mechanism of Action Oxytocin receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Preclinical Prader-Willi syndrome
- No development reported Autistic disorder
Most Recent Events
- 07 Dec 2022 No development reported - Phase-II for Autistic disorder in Norway (Intranasal) (OptiNose pipeline, December 2022)
- 23 Dec 2020 Chemical structure information added
- 09 Sep 2020 Phase II development in Autistic disorder is ongoing in Norway (Intranasal) (OptiNose pipeline, September 2020)